BioVersys AG Income Statement

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	2.47	1.21	1.14
Revenue Growth	103.46%	6.50%	-
Gross Profit	2.47	1.21	1.14
Selling, General & Admin	6.73	6.99	4.01
Research & Development	16.5	12.95	14.83
Total Operating Expenses	23.23	19.94	18.84
Operating Income	-19.96	-18.72	-17.7
Interest Income	0.23	0.93	0.49
Interest Expense	-2.07	-1.05	-0.93
Other Non-Operating Income (Expense)	-0.01	0.13	-0.16
Total Non-Operating Income (Expense)	-1.85	0	-0.6
Pretax Income	-21.81	-18.72	-18.3
Provision for Income Taxes	-0.02	-	-
Net Income	-21.83	-18.72	-18.3
Net Income to Common	-21.83	-18.72	-18.3
Net Income Growth	-	-	-
Shares Outstanding (Basic)	6	3	3
Shares Outstanding (Diluted)	6	3	3
Shares Change	68.49%	11.60%	-
EPS (Basic)	-3.89	-5.62	-6.13
EPS (Diluted)	-3.89	-5.62	-6.13
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Free Cash Flow	-22.16	-15.61	-11.7
Free Cash Flow Growth	-	-	-
Free Cash Flow Per Share	-3.95	-4.68	-3.92
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-808.87%	-1543.45%	-1553.73%
Profit Margin	-884.52%	-1543.20%	-1606.76%
FCF Margin	-897.97%	-1287.06%	-1027.57%
EBITDA	-19.67	-18.44	-17.43
EBITDA Margin	-796.84%	-1520.20%	-1529.85%
EBIT	-19.96	-18.72	-17.7
EBIT Margin	-808.87%	-1543.45%	-1553.73%
Effective Tax Rate	0.07%	0.00%	0.00%